Saturday, April 30, 2016

Oramed closes licensing, investment deal in China

Oramed closes licensing, investment deal in China

December 29, 2015 by · Leave a Comment 

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) has closed a license and investment deal with Hefei Tianhui Incubation of Technologies (HTIT) of China. Oramed has sold 1,155,367 restricted common shares to HTIT at a price of $10.39 each, or a total of $12-million. Oramed also has received regulatory approval in Israel, and closed, an out-licensing agreement with HTIT […]

Season’s Greetings (and JPM 2016)

Season’s Greetings (and JPM 2016)

December 22, 2015 by · Leave a Comment 

Tweet Wow, what an interesting year 2015 has turned out to be! Everyone at BioTuesdays would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be back in full swing with our next Tuesday Feature on January 5. On another […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

AD focus shifts to treating agitation/aggression

AD focus shifts to treating agitation/aggression

October 28, 2014 by · Leave a Comment 

Tweet After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric symptoms associated with AD, such as agitation and aggression. A case in point is Avanir Pharmaceuticals (NASDAQ:AVNR), which reported positive results in mid-September from a Phase […]

In conversation with Ron Babecoff

In conversation with Ron Babecoff

October 14, 2014 by · Leave a Comment 

Tweet As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix Biopharmaceuticals as marketing manager, where he was involved in identifying West Nile Fever treatments and building cooperation with the NIH, and forming […]

Three BT-featured CEOs sweep EY award finalist selections

Three BT-featured CEOs sweep EY award finalist selections

July 7, 2014 by · Leave a Comment 

Tweet All three finalists for the EY 2014 Ontario Entrepreneur of the Year award in the health sciences category have been featured in the past on BioTuesdays.com. They are Anthony Giovinazzo of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH), Tom Reeves of closely held Interface Biologics and Dr. Arun Menawat of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ). The Ontario winners will be announced […]

HCW starts Cesca Therapeutics at buy

HCW starts Cesca Therapeutics at buy

June 26, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Cesca Therapeutics (NASDAQ:KOOL) with a “buy” rating and a target price of $5, based on a combined discounted earnings per share and revenue multiple analysis and a comparable valuation methodology. The stock closed at $1.44 on Wednesday. Cesca’s core biotechnology franchise utilizes proprietary devices for the consistent processing, […]

Pivotal’s fight against fat gains media exposure

Pivotal’s fight against fat gains media exposure

June 25, 2014 by · Leave a Comment 

Tweet The latest issue of Bio Business magazine includes an article about the global obesity epidemic that highlights the efforts of Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to tackle the problem by focusing on the development of Omega-3 therapies and diagnostics. “The consequences of an Omega-3 deficiency could be obesity, diabetes, elevated triglycerides, high cholesterol and coronary heart […]

Stifel ups Aerie Pharma price target to $33

Stifel ups Aerie Pharma price target to $33

June 25, 2014 by · Leave a Comment 

Tweet Stifel has raised its price target for “buy-rated” Aerie Pharmaceuticals (NASDAQ:AERI) to $33 from $24 after the company released important Phase 2b data for Roclatan, its once-daily quadruple-action glaucoma treatment, “achieving all study endpoints with statistical and clinical relevance over its components (Rhopressa and latanoprost). Shares of Aerie touched a 52-week high of $29.91 […]

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Ciclofilin developing first drug for HCV/HIV-1 co-infection

June 24, 2014 by · Leave a Comment 

Tweet Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where […]

Next Page »

Email Newsletters with Constant Contact
Google+